UBS AM’s Aratana Therapeutics, Inc. PETX Stock Holding History

UBS AM’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,629	Closed	-$8.57K	–	2681
2017 Q4	$8.57K	Hold	1,629	–	–	﹤0.01%	2508
2017 Q3	$9.99K	Sell	1,629 -116	-7%	-$734	﹤0.01%	2458
2017 Q2	$12.6K	Hold	1,745	–	–	﹤0.01%	2443
2017 Q1	$9.25K	Sell	1,745 -334	-16%	-$2.25K	﹤0.01%	2398
2016 Q4	$15K	Buy	+2,079	New	+$16.8K	﹤0.01%	2367
2016 Q3	–	Sell	-61,267	Closed	-$387K	–	2609
2016 Q2	$387K	Sell	61,267 -45,418	-43%	-$292K	﹤0.01%	2095
2016 Q1	$589K	Sell	106,685 -40,251	-27%	-$151K	﹤0.01%	1848
2015 Q4	$820K	Buy	146,936 +52,128	+55%	+$345K	﹤0.01%	1818
2015 Q3	$802K	Buy	94,808 +76,508	+418%	+$1.29M	﹤0.01%	1816
2015 Q2	$277K	Buy	18,300 +4,300	+31%	+$62.1K	﹤0.01%	2415
2015 Q1	$224K	Buy	14,000 +500	+4%	+$8.9K	﹤0.01%	2432
2014 Q4	$241K	Hold	13,500	–	–	﹤0.01%	2369
2014 Q3	$136K	Buy	+13,500	New	+$164K	﹤0.01%	2460

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS AM's PETX Position: Q1 2018 in Review

UBS AM sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 1,629 shares — an estimated $8.57K sold.

UBS AM first reported a position in PETX in Q3 2014 and held it in 13 quarters. The position peaked at $820K in Q4 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

UBS AM reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
UBS AM sold 1,629 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $8.57K.
UBS AM first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 13 quarters.
UBS AM's Aratana Therapeutics, Inc. position peaked at $820K in Q4 2015.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on UBS AM's 13F filing for Q1 2018, filed 14 May 2018.